Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSP1603 in Idiopathic Pulmonary Fibrosis
NCT05119972Phase 2Completed
- Sponsor
- Raynovent Biotech
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ZSP1603 in idiopathic pulmonary fibrosis (IPF) (5 arms), sponsored by Raynovent Biotech. Primary endpoints: Treatment Emergent Adverse Events and Serious Adverse Events up to 16 weeks and Plasma concentrations of ZSP1603 up to 15 days. Started Oct 2021; status: completed.
02
Drugs
ZSP1603
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05119972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05119972.